Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RAD1 (ImmuneEditome ID:5810)

1. Gene summary of enriched editing regions for RAD1

Gene summary

Gene information	Gene symbol	RAD1
	Gene ID	5810
	GeneSynonyms	HRAD1\|REC1
	GeneCytomap	5p13.2
	GeneType	protein-coding
	GeneDescription	cell cycle checkpoint protein RAD1\|DNA repair exonuclease REC1\|DNA repair exonuclease rad1 homolog\|RAD1 checkpoint clamp component\|RAD1 homolog\|cell cycle checkpoint protein Hrad1\|checkpoint control protein HRAD1\|exonuclease homolog RAD1\|rad1-like DNA damage checkpoint protein
	GeneModificationdate	20230517
	UniprotID	O60671;D6R9A1
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr5:34905935-34906684:-	ENST00000382038.5	ENSG00000113456.17	RAD1	UTR3	AluSx1,AluJo	chr5:34905935-34906684:-.alignment
chr5:34908221-34908387:-	ENST00000341754.7	ENSG00000113456.17	RAD1	UTR3	AluSp	chr5:34908221-34908387:-.alignment
chr5:34908221-34908387:-	ENST00000382038.5	ENSG00000113456.17	RAD1	UTR3	AluSp	chr5:34908221-34908387:-.alignment

Top

2. Tumor-specific enriched editing regions for RAD1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr5:34905935-34906684:-	BRCA	EER	5.4589e-09
ENSG00000113456.17,RAD1	BRCA	EAG	2.3153e-08
chr5:34905935-34906684:-	HNSC	EER	2.4856e-03
ENSG00000113456.17,RAD1	HNSC	EAG	2.6334e-02
chr5:34905935-34906684:-	LUAD	EER	4.0691e-02
chr5:34905935-34906684:-	LUSC	EER	9.1316e-04
ENSG00000113456.17,RAD1	LUSC	EAG	1.1243e-03
chr5:34905935-34906684:-	THCA	EER	4.3790e-08
ENSG00000113456.17,RAD1	THCA	EAG	9.1241e-07
ENSG00000113456.17,RAD1	UCEC	EAG	3.4139e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000113456.17,RAD1	KIRC	Path	EAG	3.3565e-02	2.3337e-02	0.1064
chr5:34905935-34906684:-	LUSC	Path	EER	4.4498e-03	2.3914e-02	0.1047
ENSG00000113456.17,RAD1	LUSC	Path	EAG	7.2434e-03	3.2126e-02	0.0990
chr5:34905935-34906684:-	PAAD	Path	EER	1.2693e-03	3.4717e-02	0.1898
chr5:34905935-34906684:-	THCA	Path	EER	7.4019e-03	7.3296e-03	0.1233

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr5:34905935-34906684:-	LGG	EER	1.0863e-02	8.6005e-04	1.0442e-02
ENSG00000113456.17,RAD1	LGG	EAG	2.3246e-03	2.5584e-03	1.2884e-02

Top

3. Enriched editing regions and immune related genes for RAD1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr5:34905935-34906684:-

LGG

EER

ENSG00000113456,RAD1

-0.4547

7.0225e-23

2.4908e-27

-0.4542

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_G2M_CHECKPOINT

chr5:34905935-34906684:-

LGG

EER

ENSG00000139372,TDG

-0.4430

1.6440e-21

8.7734e-24

-0.4250

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_G2M_CHECKPOINT

chr5:34905935-34906684:-

LGG

EER

ENSG00000137574,TGS1

-0.4310

2.6738e-20

1.0868e-22

-0.4154

ADAR;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_G2M_CHECKPOINT

chr5:34905935-34906684:-

LGG

EER

ENSG00000168246,UBTD2

-0.4304

2.6827e-20

1.1311e-21

-0.4061

ADAR;AIFM1;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_G2M_CHECKPOINT

chr5:34905935-34906684:-

LGG

EER

ENSG00000135953,MFSD9

-0.4272

6.3086e-20

3.7633e-25

-0.4366

ADAR;AIFM1;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_MITOTIC_SPINDLE

chr5:34905935-34906684:-

LGG

EER

ENSG00000150753,CCT5

-0.4241

1.1406e-19

2.6165e-23

-0.4208

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_MYC_TARGETS_V1

chr5:34905935-34906684:-

LGG

EER

ENSG00000103429,BFAR

-0.4189

3.6556e-19

3.2278e-21

-0.4019

ADAR;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

BFAR

Monocytes

GSVA_HALLMARK_G2M_CHECKPOINT

chr5:34905935-34906684:-

LGG

EER

ENSG00000171466,ZNF562

-0.4106

1.9923e-18

2.9772e-21

-0.4022

ADAR;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Monocytes

GSVA_HALLMARK_G2M_CHECKPOINT

chr5:34905935-34906684:-

LGG

EER

ENSG00000188295,ZNF669

-0.4109

1.9923e-18

2.5269e-21

-0.4029

ADAR;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_MITOTIC_SPINDLE

chr5:34905935-34906684:-

LGG

EER

ENSG00000113569,NUP155

-0.4113

2.2146e-18

8.3785e-22

-0.4073

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

Macrophages_M0

GSVA_HALLMARK_G2M_CHECKPOINT

More results

Top

4. Enriched editing regions and immune related splicing for RAD1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr5:34905935-34906684:-

ESCA

EER

ENSG00000187954.8

chr8

144453221:144453460:144462282:144462415

-0.4359

6.4323e-04

2.5712e-08

-0.4354

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

T_cells_CD4_memory_resting

GSVA_HALLMARK_HYPOXIA

chr5:34905935-34906684:-

ESCA

EER

ENSG00000128309.12

chr22

37024191:37024810:37026998:37027053

-0.4430

9.2478e-05

9.3134e-08

-0.4445

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

T_cells_CD4_memory_resting

GSVA_HALLMARK_MTORC1_SIGNALING

chr5:34905935-34906684:-

ESCA

EER

ENSG00000124532.10

chr6

24418460:24418578:24422964:24423050

-0.2934

1.6433e-02

7.6425e-06

-0.4194

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_UP

chr5:34905935-34906684:-

ESCA

EER

ENSG00000135451.8

chr12

49323844:49324037:49324154:49324392

-0.2874

3.4695e-02

9.4757e-06

-0.4050

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

TROAP

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MTORC1_SIGNALING

chr5:34905935-34906684:-

ESCA

EER

ENSG00000132612.14

chr16

69321210:69322700:69324207:69325042

-0.4273

1.0698e-03

1.9421e-07

-0.4096

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

VPS4A

T_cells_CD4_memory_resting

GSVA_HALLMARK_HYPOXIA

chr5:34905935-34906684:-

ESCA

EER

ENSG00000132199.14

chr18

691242:693175:693881:693908

-0.3255

1.3433e-02

5.2663e-07

-0.4188

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HYPOXIA

chr5:34905935-34906684:-

ESCA

EER

ENSG00000119707.9

chr14

73099666:73100362:73103191:73103289

-0.4065

2.2874e-03

1.1167e-07

-0.4169

ADAR;AIFM1;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;SRSF1;U2AF2;UPF1

RBM25

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr5:34905935-34906684:-

ESCA

EER

ENSG00000164543.5

chr7

43619596:43623888:43624517:43625184

-0.4704

1.0613e-04

2.3519e-08

-0.4365

ADAR;DDX42;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28B;MOV10;MSI2;NOP56;NOP58;SRSF1;U2AF2;UPF1

STK17A

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

chr5:34905935-34906684:-

ESCA

EER

ENSG00000140398.9

chr15

75351945:75354818:75354963:75355215

-0.4103

2.4521e-04

1.7921e-07

-0.4515

ADAR;AIFM1;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;MOV10;NOP56;NOP58;NUMA1;SRSF1;U2AF2

Dendritic_cells_resting

GSVA_HALLMARK_P53_PATHWAY

chr5:34905935-34906684:-

ESCA

EER

ENSG00000140398.9

chr15

75351945:75354492:75354652:75354818

-0.3211

1.7537e-02

3.1981e-06

-0.4044

ADAR;AIFM1;DHX9;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;MOV10;NOP56;NOP58;NUMA1;SRSF1;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HYPOXIA

More results

Top

5. Enriched editing regions and immune infiltration for RAD1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr5:34905935-34906684:-	BLCA	EER	T_cells_regulatory_(Tregs)	6.8698e-04	-0.1846
ENSG00000113456.17,RAD1	BLCA	EAG	T_cells_regulatory_(Tregs)	3.2909e-03	-0.1592
chr5:34905935-34906684:-	BRCA	EER	T_cells_regulatory_(Tregs)	2.7807e-07	0.1609
ENSG00000113456.17,RAD1	BRCA	EAG	T_cells_regulatory_(Tregs)	7.6363e-07	0.1542
chr5:34905935-34906684:-	CESC	EER	Dendritic_cells_activated	8.0372e-03	0.1556
ENSG00000113456.17,RAD1	CESC	EAG	T_cells_CD4_memory_activated	2.4950e-03	0.1769
chr5:34905935-34906684:-	CHOL	EER	Mast_cells_activated	8.9713e-03	0.4545
chr5:34905935-34906684:-	COAD	EER	Dendritic_cells_activated	5.0567e-03	0.1871
ENSG00000113456.17,RAD1	COAD	EAG	Dendritic_cells_activated	2.2102e-02	0.1515
chr5:34905935-34906684:-	DLBC	EER	NK_cells_activated	7.8439e-04	0.5798
ENSG00000113456.17,RAD1	DLBC	EAG	NK_cells_activated	5.3998e-04	0.5939
chr5:34905935-34906684:-	ESCA	EER	T_cells_CD4_memory_resting	2.8742e-04	-0.2921
ENSG00000113456.17,RAD1	ESCA	EAG	T_cells_regulatory_(Tregs)	1.4364e-03	-0.2547
chr5:34905935-34906684:-	GBM	EER	Plasma_cells	7.4669e-03	0.2114
ENSG00000113456.17,RAD1	GBM	EAG	Plasma_cells	4.2786e-03	0.2254
chr5:34905935-34906684:-	HNSC	EER	T_cells_regulatory_(Tregs)	1.4792e-03	-0.1592
ENSG00000113456.17,RAD1	HNSC	EAG	Macrophages_M1	8.0311e-03	0.1324
chr5:34905935-34906684:-	KICH	EER	B_cells_naive	6.8960e-03	-0.4311
ENSG00000113456.17,RAD1	KICH	EAG	B_cells_naive	2.2886e-02	-0.3591
chr5:34905935-34906684:-	KIRC	EER	Monocytes	1.2156e-02	-0.1394
ENSG00000113456.17,RAD1	KIRC	EAG	T_cells_CD4_memory_resting	2.5921e-03	-0.1648
chr5:34905935-34906684:-	LAML	EER	Macrophages_M1	4.0273e-02	-0.3645
chr5:34905935-34906684:-	LGG	EER	Macrophages_M0	9.2167e-07	-0.2153
ENSG00000113456.17,RAD1	LGG	EAG	Macrophages_M0	2.5100e-07	-0.2260
chr5:34905935-34906684:-	LIHC	EER	NK_cells_activated	4.7489e-03	0.2286
ENSG00000113456.17,RAD1	LIHC	EAG	Eosinophils	4.4332e-03	-0.2225
chr5:34905935-34906684:-	LUAD	EER	T_cells_CD8	5.2640e-03	0.1309
chr5:34905935-34906684:-	LUSC	EER	Mast_cells_resting	2.2975e-05	-0.1952
ENSG00000113456.17,RAD1	LUSC	EAG	Mast_cells_resting	9.6956e-06	-0.2029
chr5:34905935-34906684:-	OV	EER	T_cells_regulatory_(Tregs)	5.8564e-03	0.1728
ENSG00000113456.17,RAD1	OV	EAG	T_cells_regulatory_(Tregs)	7.2417e-03	0.1643
chr5:34905935-34906684:-	PAAD	EER	Macrophages_M0	1.4264e-02	0.2187
ENSG00000113456.17,RAD1	PAAD	EAG	T_cells_gamma_delta	9.6498e-03	-0.2289
chr5:34905935-34906684:-	PCPG	EER	NK_cells_activated	4.5314e-02	-0.1695
ENSG00000113456.17,RAD1	PCPG	EAG	T_cells_CD4_memory_activated	3.0407e-02	0.1818
chr5:34905935-34906684:-	PRAD	EER	B_cells_memory	4.4014e-04	0.1641
ENSG00000113456.17,RAD1	PRAD	EAG	B_cells_memory	2.6340e-04	0.1695
chr5:34905935-34906684:-	READ	EER	NK_cells_activated	6.1356e-03	0.2916
ENSG00000113456.17,RAD1	READ	EAG	NK_cells_activated	3.7961e-03	0.3055
chr5:34905935-34906684:-	SARC	EER	NK_cells_resting	6.1759e-03	-0.1770
ENSG00000113456.17,RAD1	SARC	EAG	NK_cells_resting	8.5167e-03	-0.1698
chr5:34905935-34906684:-	SKCM	EER	T_cells_CD8	8.5036e-09	0.2850
ENSG00000113456.17,RAD1	SKCM	EAG	T_cells_CD8	1.1324e-08	0.2820
ENSG00000113456.17,RAD1	STAD	EAG	T_cells_follicular_helper	1.5484e-03	0.1817
chr5:34905935-34906684:-	TGCT	EER	Macrophages_M2	3.4963e-05	-0.3640
ENSG00000113456.17,RAD1	TGCT	EAG	Macrophages_M2	6.2519e-04	-0.3030
chr5:34905935-34906684:-	THCA	EER	T_cells_CD4_memory_activated	1.0128e-02	0.1181
ENSG00000113456.17,RAD1	THCA	EAG	T_cells_regulatory_(Tregs)	2.0134e-02	0.1067
chr5:34905935-34906684:-	THYM	EER	Macrophages_M1	2.1904e-03	0.3138
ENSG00000113456.17,RAD1	THYM	EAG	Macrophages_M1	2.2028e-03	0.3136
chr5:34905935-34906684:-	UCEC	EER	Macrophages_M0	3.9211e-02	-0.1909
ENSG00000113456.17,RAD1	UCEC	EAG	Macrophages_M0	2.5422e-03	-0.2731
chr5:34905935-34906684:-	UCS	EER	T_cells_CD4_memory_activated	2.8268e-02	0.2933
ENSG00000113456.17,RAD1	UCS	EAG	T_cells_CD4_memory_activated	2.1670e-02	0.3063
chr5:34905935-34906684:-	UVM	EER	T_cells_regulatory_(Tregs)	4.1499e-02	0.3018
ENSG00000113456.17,RAD1	UVM	EAG	T_cells_regulatory_(Tregs)	4.6585e-02	0.2950

Top

6. Enriched editing regions and immune gene sets for RAD1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr5:34905935-34906684:-	HNSC	EER	4.5707e-02		3.1289e-04	0.1802

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000113456.17,RAD1	LGG	EAG	1.7398e-02	-0.1053	8.9869e-10	-0.2670	1.2578e-05	-0.1921	4.7103e-03	0.1250
chr5:34905935-34906684:-	LGG	EER	4.1187e-03	-0.1268	2.0201e-11	-0.2911	1.0637e-06	-0.2141	7.6421e-03	0.1180
ENSG00000113456.17,RAD1	PAAD	EAG	4.9343e-02	0.1748	3.6926e-02	0.1854	3.8598e-02	0.1838	2.0444e-02	0.2055

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr5:34905935-34906684:-	ACC	GSVA_HALLMARK_MYOGENESIS	EER	2.6047e-03	0.3647
ENSG00000113456.17,RAD1	ACC	GSVA_HALLMARK_MYOGENESIS	EAG	1.5484e-03	0.3793
ENSG00000113456.17,RAD1	BLCA	GSVA_HALLMARK_COAGULATION	EAG	4.0770e-05	0.2209
chr5:34905935-34906684:-	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.4575e-05	0.2344
chr5:34905935-34906684:-	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.1006e-14	0.2400
ENSG00000113456.17,RAD1	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	3.0080e-10	0.1957
chr5:34905935-34906684:-	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.6684e-09	-0.3410
ENSG00000113456.17,RAD1	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.1159e-09	-0.3480
chr5:34905935-34906684:-	CHOL	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	3.1695e-02	-0.3805
ENSG00000113456.17,RAD1	CHOL	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.0151e-02	0.4089
ENSG00000113456.17,RAD1	COAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.5007e-03	0.1875
chr5:34905935-34906684:-	COAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.8942e-03	0.1986
chr5:34905935-34906684:-	DLBC	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	4.1756e-02	0.3740
ENSG00000113456.17,RAD1	DLBC	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	4.4714e-02	0.3691
ENSG00000113456.17,RAD1	ESCA	GSVA_HALLMARK_HYPOXIA	EAG	7.3548e-04	0.2692
chr5:34905935-34906684:-	ESCA	GSVA_HALLMARK_HYPOXIA	EER	1.4580e-03	0.2576
chr5:34905935-34906684:-	GBM	GSVA_HALLMARK_G2M_CHECKPOINT	EER	3.5524e-06	-0.3582
ENSG00000113456.17,RAD1	GBM	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	1.7361e-05	-0.3336
chr5:34905935-34906684:-	HNSC	GSVA_HALLMARK_COAGULATION	EER	1.7240e-05	0.2142
ENSG00000113456.17,RAD1	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.9221e-06	0.2354
ENSG00000113456.17,RAD1	KICH	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	2.1902e-02	-0.3615
chr5:34905935-34906684:-	KICH	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.6772e-03	-0.4926
chr5:34905935-34906684:-	KIRC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.0205e-03	0.1820
ENSG00000113456.17,RAD1	KIRC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	1.4126e-03	0.1745
chr5:34905935-34906684:-	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.0466e-02	-0.1712
ENSG00000113456.17,RAD1	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	7.5155e-03	-0.1949
ENSG00000113456.17,RAD1	LGG	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	4.0927e-19	-0.3815
chr5:34905935-34906684:-	LGG	GSVA_HALLMARK_G2M_CHECKPOINT	EER	1.6607e-19	-0.3854
chr5:34905935-34906684:-	LIHC	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	7.0072e-03	0.2186
chr5:34905935-34906684:-	LUAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.2803e-07	0.2450
ENSG00000113456.17,RAD1	LUAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	2.1885e-05	0.1967
ENSG00000113456.17,RAD1	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.2697e-05	0.1908
chr5:34905935-34906684:-	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.9987e-06	0.2149
ENSG00000113456.17,RAD1	MESO	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	7.2277e-05	0.4753
chr5:34905935-34906684:-	MESO	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.0549e-04	0.4657
chr5:34905935-34906684:-	OV	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.6080e-04	-0.2351
ENSG00000113456.17,RAD1	PAAD	GSVA_HALLMARK_P53_PATHWAY	EAG	6.5108e-04	0.2986
chr5:34905935-34906684:-	PAAD	GSVA_HALLMARK_P53_PATHWAY	EER	3.7672e-04	0.3132
ENSG00000113456.17,RAD1	PCPG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.7819e-02	0.1664
chr5:34905935-34906684:-	PCPG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.6249e-02	0.2028
chr5:34905935-34906684:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	7.7948e-08	-0.2486
ENSG00000113456.17,RAD1	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.9705e-07	-0.2399
chr5:34905935-34906684:-	READ	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	1.3545e-03	-0.3382
ENSG00000113456.17,RAD1	READ	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	9.6603e-04	-0.3458
chr5:34905935-34906684:-	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	6.9421e-06	0.2868
ENSG00000113456.17,RAD1	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.5896e-05	0.2752
chr5:34905935-34906684:-	SKCM	GSVA_HALLMARK_COMPLEMENT	EER	7.8001e-12	0.3357
ENSG00000113456.17,RAD1	SKCM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	2.7329e-10	0.3104
ENSG00000113456.17,RAD1	STAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	4.3233e-02	-0.1166
chr5:34905935-34906684:-	STAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.8934e-03	-0.1708
chr5:34905935-34906684:-	TGCT	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	9.2830e-06	0.3879
ENSG00000113456.17,RAD1	TGCT	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	8.8610e-06	0.3872
chr5:34905935-34906684:-	THCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	4.1709e-07	0.2302
ENSG00000113456.17,RAD1	THCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	1.3416e-06	0.2199
chr5:34905935-34906684:-	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	6.4607e-05	-0.4021
ENSG00000113456.17,RAD1	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.5107e-04	-0.3830
ENSG00000113456.17,RAD1	UCEC	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	1.7222e-02	-0.2171
chr5:34905935-34906684:-	UCEC	GSVA_HALLMARK_E2F_TARGETS	EER	5.2041e-03	-0.2567
chr5:34905935-34906684:-	UCS	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.5531e-02	0.3220
ENSG00000113456.17,RAD1	UCS	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.8001e-02	0.3151
ENSG00000113456.17,RAD1	UVM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	6.4436e-04	0.4845
chr5:34905935-34906684:-	UVM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	7.0362e-04	0.4815

Top

7. Enriched editing regions and drugs for RAD1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr5:34905935-34906684:-	ACC	Bleomycin	EER	1.9022e-02	0.2880
ENSG00000113456.17,RAD1	ACC	KIN001.135	EAG	1.0619e-02	0.3102
ENSG00000113456.17,RAD1	BLCA	BMS.509744	EAG	1.4207e-06	-0.2584
chr5:34905935-34906684:-	BLCA	BMS.509744	EER	6.9660e-08	-0.2894
ENSG00000113456.17,RAD1	BRCA	AZD6244	EAG	2.4624e-05	-0.1318
chr5:34905935-34906684:-	BRCA	A.770041	EER	5.1815e-07	-0.1574
chr5:34905935-34906684:-	CESC	CI.1040	EER	5.2907e-07	-0.2899
ENSG00000113456.17,RAD1	CESC	CI.1040	EAG	5.9258e-07	-0.2882
chr5:34905935-34906684:-	CHOL	AP.24534	EER	2.5248e-02	0.3950
ENSG00000113456.17,RAD1	CHOL	GNF.2	EAG	1.8111e-02	-0.4152
ENSG00000113456.17,RAD1	COAD	Gefitinib	EAG	7.1451e-04	-0.2225
chr5:34905935-34906684:-	COAD	Gefitinib	EER	1.2252e-03	-0.2152
chr5:34905935-34906684:-	DLBC	Bosutinib	EER	6.2413e-03	0.4958
ENSG00000113456.17,RAD1	DLBC	Bosutinib	EAG	1.8315e-03	0.5537
ENSG00000113456.17,RAD1	ESCA	Bryostatin.1	EAG	6.2278e-05	-0.3169
chr5:34905935-34906684:-	ESCA	Gefitinib	EER	5.2321e-06	-0.3634
chr5:34905935-34906684:-	GBM	BI.D1870	EER	1.4884e-06	0.3709
ENSG00000113456.17,RAD1	GBM	BI.D1870	EAG	2.2414e-05	0.3294
chr5:34905935-34906684:-	HNSC	Bexarotene	EER	1.2950e-08	-0.2809
ENSG00000113456.17,RAD1	HNSC	AZD6244	EAG	1.2741e-06	-0.2394
chr5:34905935-34906684:-	KICH	Bryostatin.1	EER	3.3290e-03	-0.4642
ENSG00000113456.17,RAD1	KICH	Bryostatin.1	EAG	1.5913e-02	-0.3789
chr5:34905935-34906684:-	KIRC	FH535	EER	9.0695e-06	0.2442
ENSG00000113456.17,RAD1	KIRC	GDC.0449	EAG	3.5952e-06	-0.2515
ENSG00000113456.17,RAD1	KIRP	KU.55933	EAG	2.4019e-03	-0.2207
chr5:34905935-34906684:-	KIRP	CEP.701	EER	1.0980e-02	-0.1876
chr5:34905935-34906684:-	LAML	Methotrexate	EER	3.1241e-03	0.5061
ENSG00000113456.17,RAD1	LAML	KIN001.135	EAG	2.0777e-03	-0.5029
ENSG00000113456.17,RAD1	LGG	Camptothecin	EAG	1.1787e-12	0.3078
chr5:34905935-34906684:-	LGG	Camptothecin	EER	4.2838e-13	0.3135
chr5:34905935-34906684:-	LIHC	Cyclopamine	EER	2.2511e-02	-0.1887
chr5:34905935-34906684:-	LUAD	AZD6244	EER	1.4242e-03	-0.1496
ENSG00000113456.17,RAD1	LUAD	AZD6244	EAG	6.6424e-03	-0.1267
chr5:34905935-34906684:-	LUSC	BIBW2992	EER	3.2321e-05	-0.1917
ENSG00000113456.17,RAD1	LUSC	BIBW2992	EAG	1.2458e-06	-0.2219
ENSG00000113456.17,RAD1	MESO	GDC0941	EAG	4.0867e-02	0.2564
chr5:34905935-34906684:-	MESO	GDC0941	EER	2.0977e-02	0.2881
chr5:34905935-34906684:-	OV	AZ628	EER	2.0603e-05	-0.2642
ENSG00000113456.17,RAD1	OV	AMG.706	EAG	1.8299e-02	0.1446
chr5:34905935-34906684:-	PAAD	BIBW2992	EER	1.4315e-04	-0.3337
ENSG00000113456.17,RAD1	PAAD	BIBW2992	EAG	1.1685e-03	-0.2849
chr5:34905935-34906684:-	PCPG	EHT.1864	EER	1.0638e-02	0.2153
ENSG00000113456.17,RAD1	PCPG	BIRB.0796	EAG	1.7052e-02	0.1999
chr5:34905935-34906684:-	PRAD	BAY.61.3606	EER	1.6446e-11	0.3088
ENSG00000113456.17,RAD1	PRAD	GDC.0449	EAG	2.5981e-11	-0.3046
ENSG00000113456.17,RAD1	READ	A.443654	EAG	5.0248e-03	0.2965
chr5:34905935-34906684:-	READ	A.443654	EER	2.7464e-03	0.3173
chr5:34905935-34906684:-	SARC	Bexarotene	EER	4.5682e-06	-0.2922
ENSG00000113456.17,RAD1	SARC	Bexarotene	EAG	2.2618e-06	-0.3003
ENSG00000113456.17,RAD1	SKCM	AZD6244	EAG	6.3497e-07	-0.2472
chr5:34905935-34906684:-	SKCM	Dasatinib	EER	5.2036e-08	-0.2710
chr5:34905935-34906684:-	STAD	BMS.708163	EER	9.9823e-04	-0.1992
ENSG00000113456.17,RAD1	STAD	CCT007093	EAG	7.0344e-03	0.1550
ENSG00000113456.17,RAD1	TGCT	Gefitinib	EAG	9.9108e-05	-0.3424
chr5:34905935-34906684:-	TGCT	Lenalidomide	EER	3.8642e-04	-0.3151
ENSG00000113456.17,RAD1	THCA	Embelin	EAG	2.9188e-12	0.3134
chr5:34905935-34906684:-	THCA	Embelin	EER	9.1788e-13	0.3206
ENSG00000113456.17,RAD1	THYM	BAY.61.3606	EAG	8.1346e-05	0.3970
chr5:34905935-34906684:-	THYM	BAY.61.3606	EER	3.9032e-05	0.4129
ENSG00000113456.17,RAD1	UCEC	Midostaurin	EAG	5.8810e-04	0.3093
chr5:34905935-34906684:-	UCEC	BIBW2992	EER	2.4754e-04	-0.3327
ENSG00000113456.17,RAD1	UCS	CCT007093	EAG	2.0941e-04	0.4759
chr5:34905935-34906684:-	UCS	CCT007093	EER	3.0122e-04	0.4654
ENSG00000113456.17,RAD1	UVM	MG.132	EAG	1.3480e-02	-0.3618
chr5:34905935-34906684:-	UVM	MG.132	EER	1.6013e-02	-0.3533

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType